Trial Profile
A Phase 1 Study of MK-5890 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 13 Apr 2023
Price :
$35
*
At a glance
- Drugs Boserolimab (Primary) ; Carboplatin; Paclitaxel; Pembrolizumab; Pemetrexed
- Indications Advanced breast cancer; Non-small cell lung cancer; Solid tumours; Triple negative breast cancer
- Focus Adverse reactions
- Acronyms MK-5890-001
- Sponsors Merck Sharp & Dohme Corp.
- 07 Nov 2022 Status changed from recruiting to active, no longer recruiting.
- 29 Jul 2021 Planned End Date changed from 27 Jan 2024 to 25 Oct 2024.
- 29 Jul 2021 Planned primary completion date changed from 27 Jan 2024 to 25 Oct 2024.